MeiraGTx Holdings (MGTX) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

$2.52

Estimate

-$0.42

Surprise

+697.3%

Revenue (period 2026-06-30)

$321.4M

Score at report (before → after)

5.3 → 5.7/10

Revenue source: xbrl.

MeiraGTx Holdings (MGTX) beat the -$0.42 estimate with adjusted EPS of $2.52 — a large 697.3% upside surprise. TrendMatrix's engine moved from Sell (5.3/10) to Hold at 5.7/10 after the report.

• RBC Capital Maintains Outperform on MeiraGTx Holdings, Raises Price Target to $27 — benzinga, 2026-08-14
• MeiraGTx Hldgs Q2 EPS $1.71 Beats $(0.46) Estimate, Sales $321.434M Beat $12.476M Estimate — benzinga, 2026-08-13
• MeiraGTx Hldgs Q2 Sales $321.434M Beat $12.476M Estimate — benzinga, 2026-08-13

TrendMatrix currently rates MGTX Buy (Wait) at 6.6/10.

1 of the last 4 quarters beat the estimate; this quarter's +697.3% surprise compares with a +25.6% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$9.87

Entry target

$9.40

Price target

$24.14

Stop

$8.78

Upside to target

+144.6%

Reward-to-risk

13.9:1

Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$936.4M

P/E (fwd)

-6.4

P/E (ttm)

11.2

52-week range

$6.62–$15.35

Off 52-week high

35.7%

RSI (14)

41

Volume vs avg

0.04×

Score today

6.6/10